Last reviewed · How we verify
SKB105 for injection Monotherapy
At a glance
| Generic name | SKB105 for injection Monotherapy |
|---|---|
| Also known as | SKB105 Antibody-Drug Conjugate(ADC) in solid tumors |
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SKB105 for Injection in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: